LRRK2 Degrading Compounds for Parkinson's Disease Treatment

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Published September 6th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a new patent application (US20260085066A1) detailing bifunctional compounds designed to degrade LRRK2, a protein implicated in Parkinson's Disease. The application covers pharmaceutical compositions and methods for treating LRRK2-associated disorders.

View original document View source feed page

What changed

This document is a patent application (US20260085066A1) filed with the USPTO on September 6, 2023, concerning novel bifunctional compounds that induce the degradation of Leucine Rich Repeat Kinase 2 (LRRK2). The application outlines pharmaceutical compositions containing these compounds and their associated methods of use for treating disorders linked to LRRK2, specifically mentioning Parkinson's Disease.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in therapeutic treatments for Parkinson's Disease, which may impact research and development strategies for pharmaceutical and biotechnology companies operating in this therapeutic area. Companies involved in LRRK2 research or Parkinson's disease treatments should monitor the progress of this patent application and related intellectual property.

Source document (simplified)

← USPTO Patent Applications

LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE

Application US20260085066A1 Kind: A1 Mar 26, 2026

Inventors

Steven M. Sparks, Handing Dong, Michael Berlin

Abstract

The present disclosure relates to bifunctional compounds that cause the degradation of LRRK2; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with LRRK2, including Parkinson's Disease.